Showing results (21-30 of 10,058) with videos related to
Sort By:
Pageof 1,006
Current Pharmaceutical Design|December 7, 2010
Therapeutic antibodies in HIV treatment--classical approaches to novel advancesIrene A Abela, Lucy Reynell, Alexandra TrkolaCurrent Pharmaceutical Design|December 7, 2010
Chronic hepatitis C, insulin resistance and vascular diseaseAndreja Trpkovic, Edith Stokic, Djordje Radak, et al.Current Pharmaceutical Design|December 7, 2010
Herbal medicines and nutraceuticals for diabetic vascular complications: mechanisms of action and bioactive phytochemicalsEshaifol A Omar, Antony Kam, Ali Alqahtani, et al.Current Pharmaceutical Design|December 7, 2010
Targeting IL-23 and Th17-cytokines in inflammatory bowel diseasesDaniela De Nitto, Massimiliano Sarra, Maria Laura Cupi, et al.Current Pharmaceutical Design|December 7, 2010
Current developments for the diagnosis and treatment of irritable bowel syndromeOliver Grundmann, Saunjoo L Yoon, Baharak MoshireeCurrent Pharmaceutical Design|February 24, 2011
Self assembling polymers as polymersomes for drug deliveryJay Prakash Jain, Wubeante Yenet Ayen, Neeraj KumarCurrent Pharmaceutical Design|February 26, 2011
Matter of life and death: the pharmacological approaches targeting apoptosis in brain diseasesVirve Cavallucci, Marcello D'AmelioCurrent Pharmaceutical Design|February 26, 2011
Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanismsJózefa Węsierska-Gądek, Margarita MaurerCurrent Pharmaceutical Design|March 3, 2011
Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disordersSilvia Paba, Roberto Frau, Sean C Godar, et al.Current Pharmaceutical Design|March 3, 2011
Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophreniaDana V Ferraris, Takashi TsukamotoPageof 1,006